Gujarat Themis Biosyn Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 October 2024.

Powered by Capital Market - Live News

This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore.

Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter.

Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24).

Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review.

As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year.

Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O.

The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday.

In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period.

Powered by Capital Market - Live News

The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024.

Powered by Capital Market - Live News